CohBar Company Overview
CohBar
About CohBar
CohBar (NASDAQ:CWBR) is a biotechnology company focused on the research and development of mitochondria-based therapeutics (MBTs), an innovative class of drugs intended to treat diseases associated with aging and metabolic dysfunction. The company's pipeline includes projects aimed at tackling a wide range of conditions, including obesity, type 2 diabetes, cancer, and cardiovascular diseases, by leveraging the therapeutic potential of mitochondrial-derived peptides (MDPs). With a mission to extend healthy lifespan and improve the quality of life, CohBar's ongoing research and development activities underscore its commitment to pioneering the exploration of mitochondria's role in health and disease.
What is CohBar known for?
Snapshot
2007
Year founded
6
Employees
Menlo Park, United States
Head office
Loading Map...
Operations
All Locations
Edison, US
Products and/or services of CohBar
- Mitochondria based therapeutics for age-associated diseases, focusing on metabolic disorders.
- Development of peptides derived from mitochondria for potential treatment of cancer.
- Research into mitochondrial-derived peptides (MDPs) for cardiovascular diseases.
- Exploring therapeutic potentials in neurodegenerative diseases with mitochondrial peptides.
CohBar executive team
- Dr. Pinchas Cohen Dean, M.D., Ph.D.Founder & Member of Scientific Advisory Board
- Dr. Nir Yacov Barzilai M.D.Founder & Member of Scientific Advisory Board
- Dr. John M. Amatruda M.D., Ph.D.Co-Founder
- Ms. Jordyn TaraziDirector of Investor Relations